Hector Gallice

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

Innovacom Gestion SAS (Innovacom) is a venture capital firm founded in 1988 and a subsidiary of Turenne Capital Partenaires. Innovacom is headquartered in Paris, France with additional offices in Stockholm and San Francisco.

Evolem SAS (Evolem) is a private equity and venture capital subsidiary of Bruno Rousset SAS founded in 1996 by Bruno Rousset. The firm is headquartered in France.

Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector.

Naxicap Partners SA operates as a private equity firm. It invests in hospitals, pharmaceuticals, business services, information technology, textile, and consumer goods sectors. The company was founded in 1995 and is headquartered in Paris, France.

Participex Gestion SAS is a Private Equity firm, a subsidiary of Vauban Partenaires SA founded in 1974. Participex Gestion SAS is headquartered in Lille, France.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

La Redoute SAS operates as an online platform for electronic shopping. It offers clothing and accessories for men, women, and children. The firm also sells products for health, gardens, homes, and hobbies. Its services include delivery, after-sales, item exchange, and home installation. The company was founded by Joseph Pollet in 1835 and is headquartered in Roubaix, France.

M Capital Partners SASU is an Independent Private Equity firm founded in 2001 by Rudy Secco. M Capital Partners SASU is headquartered in Toulouse.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

D&P Finance SA (D&P) is the private equity firm of Didier Calmels. Formerly part of the D&P group, the firm was established in 1994 and is located in Paris. D&P manages a series of private equity funds backed by French financial institutions, insurance companies and entrepreneurs.

Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

MW Gestion SA is an independent financial asset management firm headquartered in Paris, France. The firm was founded in 1992 and offers UCITS funds and discretionary mandates, specialized in share and bond investments to individuals and institutional clients.

Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Dzeta Conseil SASU (Dzeta Conseil) is an independent private equity firm headquartered in Paris, France. It was founded in 2009 by Claude Harmon.

Credit Mutuel Equity SA is the private equity and venture capital subsidiary of Crédit Industriel et Commercial SA, which is ultimately-owned by Groupe Crédit Mutuel. The firm was founded in 1956. It is headquartered in Paris, with additional offices across France, Canada, USA, Switzerland, Germany, and United Kingdom.

Germitec SA engages in the research, design, and marketing of medical hygiene systems. It develops Antigermix, which is used in disinfecting heat-sensitive medical instruments. The company was founded in 2005 and is headquartered in Ivry-sur-Seine, France.

Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France.

Extens SAS (Extens) is an independent venture capital firm headquartered in Paris, France. The firm was founded by Arnaud Houette and Quentin Jacomet in 2013.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Essling Capital SAS (Essling Capital) is an independent private equity firm founded in 2016 by Frank-Noël Vandenberghe. The firm is headquartered in Paris, France.

Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.